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Abstract Adipogenesis, a key step in the pathogenesis of
obesity, involves extensive ECM remodeling, changes in
cell-ECM interactions, and cytoskeletal rearrangement.
Matricellular proteins regulate cell-cell and cell-ECM
interactions. Evidence in vivo and in vitro indicates that
the prototypic matricellular protein, SPARC, inhibits adipo-
genesis and promotes osteoblastogenesis. Herein we dis-
cuss mechanisms underlying the inhibitory effect of
SPARC on adipogenesis. SPARC enhances the Wnt/β-
catenin signaling pathway and regulates the expression and
posttranslational modification of collagen. SPARC might
drive preadipocytes away from the status of growth arrest
and therefore prevent terminal differentiation. SPARC
could also decrease WAT deposition through its negative
effects on angiogenesis. Therefore, several stages of white
adipose tissue accumulation are sensitive to the inhibitory
effects of SPARC.
Keywords SPARC.Adipocyte.Obesity.Collagen.
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Abbreviations
BM basement membrane
C/EBP CAAT/enhancer-binding protein
ECM extracellular matrix
FN fibronectin
GSK glycogen synthase kinase
ILK integrin-linked kinase
LN laminin
MSC mesenchymal stem cell
PDGF platelet-derived growth factor
PPAR peroxisome proliferator-activated receptor
SPARC secreted protein acidic and rich in cysteine
TGF transforming growth factor
TCF/LEF T-cell factor/lymphoid-enhancing factor
VEGF vascular endothelial growth factor
WAT white adipose tissue
Introduction
Obesity, an energy balance disorder represented as excessive
accumulation of white adipose tissue (WAT), is a major
public health problem in developed countries. The cellular
composition of WAT includes primarily adipocytes and
preadipocytes, as well as endothelial cells and macrophages.
Obesity is the result of increases in cell size (adipocyte
hypertrophy) and cell number. Adipocytes are not only the
storage depots of energy, but also the source of various
cytokines and hormones. These so-called adipokines, e.g.,
tumor necrosis factor-α, leptin, adiponectin, and resistin,
target the central nervous system and peripheral tissues
(WAT, liver and muscle) to modulate energy metabolism
(Gregoire et al. 1998; Rosen and Spiegelman 2000).
Adipocytes are derived from multipotent mesenchymal
stem cells (MSC). The first phase of adipogenesis is fate
determination, which involves the conversion of MSCs to
preadipocytes. The second phase, known as terminal
differentiation, is the process by which preadipocytes
differentiate into adipocytes. Many studies have defined
mechanisms by which transcription factors and hormones
regulate terminal differentiation in cultured 3T3-L1/F442
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tional regulation. The first step is induction of the expression
and activation of CAAT/enhancer-binding protein β
(C/EBPβ)a n dC / E B P δ, which, in turn, induce the expression
of C/EBPα and peroxisome proliferator-activated receptor γ
(PPARγ), the central transcriptional regulators for adipo-
genesis. A variety of signaling pathways regulate adipo-
genesis,includingtransforminggrowthfactor(TGF)-β,tu mo r
necrosis factor-α, Wnt, insulin/ insulin-like growth factor-1,
and other growth factors.
Extracellular matrix (ECM) is crucial for tissue and organ
development; however, it has not received sufficient atten-
tion in adipose tissue because of its apparent paucity (due to
the minimal space ECM could occupy) and the difficulties
associated with analysis of ECM components. The main
constituents of ECM in WAT are collagen (types I, IV, and
VI), laminin (LN-1, 8), fibronectin (FN), hyaluronan, and
proteoglycans (Khan et al. 2009;W i l s i ee ta l .2005).
Adipogenesis involves extensive ECM remodeling,
changes in cell-ECM adhesion, and cytoskeletal rearrange-
ment. Cell-associated ECM switches from a FN-enriched
matrix into basement membrane (BM). ECM components
have major effects on preadipocyte differentiation. For
example, FN inhibits adipogenesis, whereas LN and type
IV collagen enhance adipogenesis, in two-dimensional cell
culture (O’Connor et al. 2003; Rodriguez Fernandez and
Ben-Ze’ev 1989; Spiegelman and Ginty 1983).
Matricellular proteins regulate cell-cell and cell-ECM
interactions, and they are involved in developmental and
disease/stress-induced remodeling (Bornstein and Sage
2002). These proteins interact with ECM components, as
well as with cell surface receptors and growth factors, to
modulate cell signaling. Secreted protein acidic and rich in
cysteine (SPARC) is the first known matricellular protein
linked to the ‘balance’ of WATs. SPARC-null mice exhibit
increased accumulation of WAT (Bradshaw et al. 2003a).
There are increases in both cell size and cell number in
WAT of SPARC-null mice compared with that of WT mice
(Bradshaw et al. 2003b). SPARC inhibits differentiation of
preadipocytes (or MSCs) into adipocytes but favors that of
osteoblastocytes (Delany et al. 2003; Nie and Sage 2009).
SPARC is enriched in WAT, and both subcutaneous and
mesenteric WATs show high levels of SPARC mRNA
(Takahashi et al. 2001). Expressed in bone marrow MSCs,
preadipocytes, and mature adipocytes, SPARC is enhanced
at certain stages of adipogenesis (Chavey et al. 2006;
Delany et al. 2003;N i ea n dS a g e2009). The ECM
remodeling accompanying adipogenesis requires matricel-
lular proteins, especially SPARC, to stabilize the tissue and
maintain the balance of lipogenesis and lipolysis. Indeed,
SPARC is significantly enhanced in obese mouse WAT
(Tartare-Deckert et al. 2001). In humans, the plasma
concentration of SPARC was correlated positively with
body mass index (Takahashi et al. 2001). The inflammatory
environment of obesity is associated with increased TGFβ
(Keophiphath et al. 2009), which causes fibrosis and might
increase the expression of SPARC. ECM remodeling
requires SPARC to facilitate the development of mature
collagen fibrils and other post-translational modifications of
collagen. The inflammatory environment of obesity thereby
induces fibrosis to restrain the overgrowth of WAT.
However, other adipokines and metabolic regulation may
override the effects of TGFβ, SPARC, and collagen.
ECM remodeling requires SPARC, whereas SPARC, to
some extent, can prevent hypertrophy of adipocytes and
hyperplasia of adipocyte progenitors. According to the
“critical fat cell size hypothesis”, upon metabolic stimula-
tion, lipid accumulates in adipocytes and cell size increases.
When cell size reaches a certain threshold, signaling favors
adipocyte differentiation; alternatively, preadipocyte prolif-
eration is activated and cell number will increase. The
disorganized collagen matrix in SPARC-null WAT might
allow adipocytes to grow to a greater size and would
eventually lead to hyperplastic WAT. Loss of SPARC
expression enhances adipocyte differentiation and might
improve preadipocyte proliferation. In addition, SPARC
appears to regulate appetite control such that total WAT
accumulation is enhanced.
ECM and adipogenesis
Adipogenesis is characterized by conversion of a FN-rich
stromal ECM to a LN-rich BM; consistently, integrin
expression switches from α5 (FN) to α6 (LN) (Liu et al.
2005). LN and matrigel enhance adipogenesis; FN and
poly-L-lysine exert inhibitory effects on adipogenesis
(Gregoire et al. 1998; Liu et al. 2005;O ’Connor et al.
2003). The inhibitory activity of FN requires cell spreading,
and cytochalasin D, via its disruption of actin filaments, can
overcome the inhibitory effects of FN (Spiegelman and
Ginty 1983). Remodeling of ECM proteins induces changes
in the cytoskeleton. FN is linked to actin stress fibers,
whereas LN polymerization on the cell surface promotes
the formation of a cortical actin network (Colognato et al.
1999). During adipogenesis, SPARC enhances the deposi-
tion of FN and the expression of its receptor, α5 integrin
(Nie and Sage 2009). In lung fibroblasts, SPARC enhanced
cell-mediated partial unfolding of FN molecules and FN-
induced stress fiber formation through ILK-dependent
contractile signaling (Barker et al. 2005). The unfolding
of FN molecules is an important step in FN fibril formation.
SPARC might also enhance this process through ILK
signaling and contribute to the increased deposition of FN.
BM components support the survival and maturation of
adipocytes. Injections of BM proteins, in combination with
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injection (Kawaguchi et al. 1998). SPARC inhibits the
expression of the LN α1 chain and one of its major
receptors, α6 integrin, as well as the deposition of LN itself
during adipogenesis (Nie and Sage 2009). SPARC regulates
the secretion and deposition of LN in lens cells (Weaver et
al. 2006). The expression of α6 integrin correlates with the
growth-arrest of preadipocytes during adipogenesis, and it
favors differentiation over proliferation of preadipocytes
(Liu et al. 2005). α6 integrin and LN enhance adipogenesis
and lipid accumulation. The interaction of LN and α7β1
integrin is required for basal lamina formation and actin
reorganization in muscle cells (Colognato et al. 1999).
Similarly, α6 integrin might berequired for receptor-facilitated
LN self-assembly, basal lamina formation, actin reorganiza-
tion,andotheradipogenicsignalingevents.Moreover,SPARC
interacts with type IV collagen (Maurer et al. 1995). SPARC is
required for collagen-IV-dependent stability of basal lamina
in Drosophila embryos (Martinek et al. 2008). Therefore, it is
likely that SPARC inhibits adipogenesis in part by interfer-
ence with the formation of BM.
Collagen contributes to the support of tissues and can
thereby regulate adipogenesis. In C. elegans, diminished
expression of collagen by RNAi causes substantial reduction
in fat, whereas RNAi targeting of collagen triple helical
repeats increases fat content (Ashrafi et al. 2003). The
predominantly-expressed collagen mRNAs in WAT encode
types I, IV, and VI (Khan et al. 2009). Type I collagen forms
collagen fibrils, found in the interstitial space; type IV
collagen contributes to the BM, whereas type VI collagen
interacts with both type I and IV collagen (Kuo et al. 1997).
In 2-dimensional cell culture, the effect of collagen fibril
structure on adipocyte differentiation is minimal (O’Connor
et al. 2003). However, in a 3-dimensional collagen matrix
and in vivo, adipogenesis is significantly reduced (>80%) in
membrane-type 1 matrix metalloproteinase (MT1-MMP)
null preadipocytes due to diminished collagen remodeling
(Chun et al. 2006). There is less collagen degradation and a
more dense collagen fibrillar network in WAT of MT1-
MMP-null mice compared with that of WT mice (Chun et
al. 2006). The absence of MMP-19, which cleaves type IV
collagen, enhances diet-induced obesity (>2fold) and
increases adipocyte size (Pendas et al. 2004). Consistently,
mice receiving a high fat diet and treated with MMP
inhibitors exhibited less WAT and increased numbers of
adipocytes. These data indicate that the collagen network is
a barrier for adipogenesis and that collagen remodeling is
required for adipocytes to grow and divide.
SPARC binds to collagen types I and IV (Hohenester et
al. 2008; Maurer et al. 1995), regulates fibrillogenesis of
type I, and is required for the development of mature cross-
linked collagen fibrils. In the skin of SPARC-null mice,
hydroxyproline content is reduced, and the collagen fibers
are smaller, immature, and less crosslinked (Bradshaw et al.
2002; Bradshaw et al. 2003a). There is also less hydroxy-
proline in the WAT of these animals (Bradshaw et al.
2003b), and the collagen fibers appear to be less mature.
The decreased collagen content and disorganized collagen
network in SPARC-null mice might be more susceptible to
protease degradation and remodeling, properties allowing
adipocytes to grow to a greater size and contributing to
hyperplastic WAT.
Type VI collagen modulates collagen fibrillogenesis,
affects FN assembly, and is anchored to BM through its
interaction with type IV collagen (Kuo et al. 1997;
Minamitani et al. 2004; Sabatelli et al. 2001). Because
WATs from collagen VI-null mice exhibit a substantially
increased interstitial space among mature adipocytes, type
VI collagen might serve as a link between the BM network
and collagen fibrils (types I and III) (Khan et al. 2009).
Type VI collagen also regulates WAT development. Colla-
gen VI-null mice show increased adipocyte size, although
the total weight of WAT is lower than that of wild-type mice
(Khan et al. 2009). Because SPARC-null mice have
increased levels of soluble type VI collagen in their dermis
(Bradshaw et al. 2002), SPARC might affect the expression,
folding, post-translational modification, and/or secretion of
type VI collagen in WAT. Therefore, SPARC could regulate
adipogenesis through type VI collagen.
Wnt/β-catenin and adipogenesis
Preadipocytes enter a state of growth arrest in the G1 phase
of the cell cycle prior to their terminal differentiation.
SPARC inhibits preadipocyte adhesion by its interaction
with integrin α5β1 and enhances cell migration. In melano-
ma cells, SPARC enhances snail activity and downregulates
E-cadherin (Robert et al. 2006). If SPARC diminishes
E-cadherin in preadipocytes, this change would lead to
nuclear translocation and accumulation of β-catenin. Thus,
preadipocytes could exit from the state of growth arrest but
not be able to terminally-differentiate into adipocytes.
MSC can differentiate into a variety of tissues,
including muscle, bone, cartilage, and fat. Wnt signaling,
one of the key factors controlling MSC fate, inhibits
adipogenesis and enhances myogenesis or osteoblasto-
genesis (Arango et al. 2005; Bodine et al. 2004).
Constitutively-activated Frizzled (Fz) increases the stability
of β-catenin, inhibits apoptosis, inhibits adipogenesis, and
induces osteoblastogenesis (Kennell and MacDougald 2005).
Disruption of Wnt/β-catenin signaling leads to spontaneous
adipocyte differentiation (Longo et al. 2004;R o s se ta l .
2000). Endogenous Wnts, especially Wnt10b, restrain
preadipocyte differentiation (Longo et al. 2004). Activation
of this pathway is sufficient to inhibit the differentiation and
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and PPARγ (Farmer 2005;R o s se ta l .2000). Wnt proteins
bind to Fz receptors and low-density lipoprotein receptor-
related protein (LRP) coreceptors 5/6 to activate several
signaling pathways. Importantly, the inhibition of glycogen
synthase kinase 3β (GSK3β) via Wnt results in the
stabilization of β-catenin in the cytoplasm, and reduces its
proteosomal degradation. After translocation to the nucleus,
β-catenin binds to and coactivates transcription factors that
include members of the T-cell factor/lymphoid-enhancing
factor (TCF/LEF) family (Christodoulides et al. 2009).
SPARC-null mice exhibit increased accumulation of fat
and a decrease in bone mass. The direction of differentiation
of MSCs favors bone over fat in these animals. Recently we
have shown that SPARC inhibits adipogenesis and enhances
osteoblastogenesis by its enhancement of the accumulation of
β-catenin (Nie and Sage 2009). Both exogenous and
endogenous SPARC promote the accumulation of β-
catenin. During early adipogenesis, the decrease in the
abundance of β-catenin coincides with the accumulation of
PPARγ (Moldes et al. 2003). PPARγ can suppress Wnt
signaling by its targeting of phosphorylated β-catenin to the
proteasome (Girnun et al. 2002; Liu et al. 2006;M o l d e se ta l .
2003). Conversely, β-catenin not only inhibits expression of
PPARγ, but also inhibits its transcriptional activity through a
direct interaction involving its TCF/LEF binding domain
(Liu et al. 2006). In addition, Wnt/β-catenin enhances
osteoblastogenesis through repression of the expression of
C/EBPα and PPARγ (Kang et al. 2007). Consistently,
SPARC inhibited the expression of PPARγ and C/EBPα at
later stages of differentiation. These data provide further
evidence that SPARC inhibits the key transcriptional cascades
of adipogenesis through the Wnt/β-catenin pathway.
The Wnt/β-catenin pathway also plays an essential role
during skeletal development. Inactivation of β-catenin in
MSCs blocks osteoblast differentiation (Hartmann 2006).
During postnatal development, β-catenin is also involved in
osteoblast proliferation and maturation, and in osteoclasto-
genesis (Glass et al. 2005; Glass and Karsenty 2006).
Conditional inactivation of β-catenin in skeletal progenitors,
or inactivation ofWnt10bor Lrp5 (aWnt receptor), results in
low bone mass (osteopenia) (Hartmann 2006). The β-
catenin-TCF/LEF complex regulates the expression of the
osteogenesis genes, RUNX2, RANK ligand, osteoprote-
gerin, and osteocalcin (Dong et al. 2006; Glass et al. 2005;
Spencer et al. 2006). Similarly, SPARC-null mice develop
osteopenia that becomes more severe as the animals age
(Delany et al. 2000). Consistently, both MSCs from SPARC-
null bone marrow and preadipocytes from SPARC-null WAT,
show an increased tendency to form adipocytes and a
decreased tendency to form osteoblasts (Delany et al. 2003).
Therefore, SPARC could regulate osteoblast formation,
maturation, and survival through the Wnt/β-catenin pathway.
As shown in Fig. 1, we also demonstrated that SPARC
activates integrin-linked kinase (ILK), which in turn
phosphorylates and inhibits GSK3β activity and leads to
the accumulation of β-catenin in both the cytosol and the
nucleus (Nie and Sage 2009). Which protein and/or protein
complex is downstream of SPARC that affects the
activation of ILK? SPARC interacts not only with ECM
components, but also with integrins and growth factors;
therefore, a possible pathway is the activation of ILK
through an interaction of SPARC with integrins. SPARC
interacts with β1 integrin and subsequently enhances the
activation of ILK in lens epithelial cells (Weaver et al.
2008). In preadipocytes, SPARC-mimicking peptides bind to
α5β1in te gr in(N ieetal .2008). SPARC enhances the activity
of ILK at an early stage of adipocyte differentiation, and an
ILK-specific inhibitor partially blocks the inhibitory effects
α β
β−catenin
PI3K
β−catenin
S
RTK
PPARγ
S GF
TCF/LEF
ILK
GSK3β
nuclear membrane
Fig. 1 SPARC (S,i nred star) inhibits adipogenesis by its
enhancement of β-catenin signaling. SPARC activates ILK, which in
turn phosphorylates GSK-3β and inhibits its activity. GSK-3β activity
is required for ubiquitin-mediated degradation of cytosolic β-catenin.
Inhibition of GSK-3β activity results in the accumulation of β-
catenin, which can translocate to the nucleus. In the nucleus, β-catenin
can inhibit the activity of PPARγ, activate TCF/LEF transcripotion
factors, and regulate the expressions of many genes including those
encoding growth factors and ECM proteins. SPARC could activate
ILK through an interaction with integrins or with receptor tyrosine
kinases (receptors of growth factors). S, SPARC; GF, growth factors;
RTK, receptor tyrosine kinase; PI3K, Phosphoinositide-3 kinase; α
and β, α and β subunits of integrin; TCF/LEF, T-cell factor/lymphoid-
enhancing factor
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interaction with the cytoplasmic tail of β1/β3 integrins
(Oloumi et al. 2004); thus SPARC might enhance ILK
activity through β1/β3 integrins. Moreover, SPARC partially
preserves cell adhesion to ECM during an early stage of
adipogenesis (Nie and Sage 2009). In the absence of
SPARC, preadipocytes partially detach, focal adhesion
complexes are lost, focal adhesion kinase (FAK) and ILK
activity are decreased, and the ECM is changed from a FN-
enriched matrix to a LN-enriched matrix. The partial
detachment from FN-enriched ECM is crucial to allow cells
to retract and for lipid to accumulate. SPARC might interfere
with the mechanosensor function of integrin(s) and inhibit
both outside-in and inside-out signaling of this receptor. In
addition, the FN-ECM matrix is reorganized, and possibly
cleaved, during an early stage of adipogenesis (Selvarajan et
al. 2001). The changes in the interaction of FN with its
cognate integrin might lead to conformational changes of the
receptor and cell rounding or contraction. SPARC could
interact with integrin to maintain the activity of ILK and
FAK in preadipocytes (Fig. 2, state 4). Consequently, ILK
activity would preserve the linkage among ECM compo-
nents, integrins, and the actin cytoskeleton, with subsequent
preservation of focal adhesion complexes. Consistent with
this proposal, SPARC also induces the phosphorylation and
activation of FAK in glioma cells (Shi et al. 2007).
SPARC might retard the deadhesion process during an
early stage ofadipocytedifferentiation byits interferencewith
integrin-mediated signaling. The adhesive effect of SPARC in
adipogenesis is not inconsistent with the anti-adhesive
function of SPARC in endothelial and glioma cells (Rempel
etal.2001;S a g ee ta l .1989). During the process of adhesion,
SPARC might compete with certain ECM proteins for their
binding sites on integrins (Fig. 2, state 2). SPARC could in
fact act as a fine tuner of integrin signaling.
Alternatively,SPARCcouldactivateILKbyitsinterference
with growth-factor signaling (Fig. 1). Insulin, platelet-derived
growth factor (PDGF), and other growth factors can stimulate
ILK activity through phosphoinositide 3-kinases (Dedhar et
al. 1999; Delcommenne et al. 1998). SPARC is involved in
growth factor signaling, e.g., it binds to PDGF and vascular
endothelial growth factor (VEGF), and inhibits the binding of
these growth factors to their cognate receptors (Battegay et
al. 1994; Kupprion et al. 1998;N o z a k ie ta l .2006; Raines et
al. 1992). Together with integrins, growth factors also
regulate adipogenesis. However, further investigation is
required to ascertain whether SPARC activates ILK by
signaling via growth-factor.
During adipogenesis, Wnt/β-catenin signaling leads to
the remodeling of ECM and changes in the expression of
integrin and ECM components. Although it is not clear
whether Wnt/β-catenin directly regulates the expression of
integrins or any ECM components, our evidence indicates
that β-catenin-mediated signaling is involved in the
regulation of integrin expression. LiCl, a strong inducer of
β-catenin signaling, significantly inhibited the expression
of α6 integrin. ILK activity, which also enhances β-catenin
accumulation, is required for SPARC to inhibit the
expression of α6 integrin. Because Wnt/β-catenin has been
shown to regulate ECM remodeling and expression through
PPARγ (Liu et al. 2006), SPARC might therefore affect
ECM composition through β-catenin-mediated signaling.
Angiogenesis
WAT is highly vascularized, and each adipocyte is
nourished by an extensive vasculature. Adipogenesis is
associated with, and in most cases dependent on, angio-
genesis. Fetal adipocyte development is spatially and
temporally related to the development of microvessels.
Arteriolar development precedes adipocyte differentiation
in internal WAT depots (Hausman and Richardson 2004).
Interestingly, adipocytes and endothelial cells might share a
common progenitor (Planat-Benard et al. 2004). Adipose
α β
α
α β
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S
L
α β
L S
1
3
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S
S
Fig. 2 A model showing how SPARC (S,i nred star) can interfere
with integrin signaling. 1) The inactive state of an integrin. 2) During
the adhesion process, SPARC competes with an integrin ligand (L) for
its binding site, and prevents the conformational change of the integrin
to active state (dashed arrow). Therefore, SPARC inhibits the
formation of focal adhesion and outside-in signaling. 3) ligand-
binding (active) state of integrin. 4) SPARC slow down cell
deadhesion. During inside-out signaling and subsequent deadhesion
process, SPARC interacts with integrin and prevent the conformational
change of integrin to state 1 (dashed arrow). Thus, SPARC preserve
focal adhesions and inhibits inside-out signaling. We currently cannot
predict the binding sites of SPARC on integrin in either state 2 or 4. L,
ligandofintegrin;S,SPARC; α and β,α and β subunitsofintegrin; pink
circle, β-propeller domain of integrin α subunit; yellow circle, I domain
of integrin α subunit; green circle, I-like domain of integrin β subunit
SPARC functions as an inhibitor of adipogenesis 251progenitor cells reside in the adipose vasculature as
demonstrated in PPARγ-tet transactivator knock-in mice
(Tang et al. 2008;T r a k t u e ve ta l .2008). Moreover,
blockade of VEGF signaling can inhibit WAT formation in
vivo (Fukumura et al. 2003), whereas depletion of adipose
vasculature results in WAT resorption (Kolonin et al. 2004).
SPARC is involved in the regulation of angiogenesis.
Proteolytic fragments of SPARC have different effects on
angiogenesis, and the function of SPARC is cell/tissue/
condition-specific and concentration-dependent. The effect
of SPARC depends on the exposed epitope and its
conformation, and on the availability of binding partners/
targets. SPARC inhibits endothelial cell proliferation and
increases the permeability of endothelial monolayers in
vitro. SPARC peptides 2.1 (in the follistatin domain) and
4.2 (in the C-terminal Ca
++ binding EF-hand) exert
inhibitory effects on cell proliferation (Jendraschak and
Sage 1996). SPARC also interacts with PDGF and
interferes with PDGF signaling that indirectly promotes
angiogenesis (Raines et al. 1992). SPARC contains a
copper-binding motif (K)GHK that stimulates endothelial
cell proliferation and angiogenesis in vivo and in vitro
(Lane et al. 1994). There is a heightened neovascular
response in sponge implants in SPARC-null, compared to
wild-type mice. (Bradshaw et al. 2001)
In WATs, the driving forces in angiogenesis are hypoxia
and signals from the sympathetic nervous system (Cao
2007). Both conditions activate VEGF signaling and
downregulate endogenous inhibitors, such as thrombospon-
din 1. VEGF-A plays a central role in the angiogenesis of
WATs. VEGF-A signaling is balanced by VEGFR-1 and -2:
VEGFR-1 mediates an inhibitory signal, and VEGFR-2, a
stimulatory signal. SPARC binds to VEGF-A and inhibits
the activation of VEGFR-1 but not that of VEGFR-2 in
vitro (Kupprion et al. 1998). Consistent with these data,
SPARCcompeteswithVEGF-Aforthebindingandactivation
of VEGFR-1 and thereby enhances choroidal neovasculariza-
tion (Nozaki et al. 2006). Both adipose stromal cells and (pre)
adipocytes produce VEGF-A. In WATs, SPARC might also
limit the activation of VEGFR-1 by VEGF-A, and thereby
promote angiogenesis, during adipogenesis.
Conclusions
1) SPARC inhibits adipogenesis and enhances osteoblasto-
genesis by its enhancement of the Wnt/β-catenin pathway; 2)
SPARC also inhibits adipogenesis through its regulation of
collagen expression and deposition; 3) SPARC appears to
drive preadipocytes from the status of growth arrest and
therefore prevents terminal differentiation; 4) SPARC might
inhibit adipogenesis through its regulation of adipose tissue
angiogenesis. Further investigation is needed to uncover the
mechanisms underlying the inhibitory effects of SPARC on
adipogenesis in vivo. We also cannot exclude the possibility
that SPARC affects lipid metabolism in other organs, e.g.,
brain, liver, and pancreas, and thereby affects lipid accumu-
lation in WAT.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
Arango NA, Szotek PP, Manganaro TF, Oliva E, Donahoe PK,
Teixeira J (2005) Conditional deletion of beta-catenin in the
mesenchyme of the developing mouse uterus results in a switch
to adipogenesis in the myometrium. Dev Biol 288:276–283
Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J,
Ruvkun G (2003) Genome-wide RNAi analysis of Caenorhabdi-
tis elegans fat regulatory genes. Nature 421:268–272
Barker TH, Baneyx G, Cardo-Vila M, Workman GA, Weaver M,
Menon PM, Dedhar S, Rempel SA, Arap W, Pasqualini R, Vogel
V, Sage EH (2005) SPARC regulates extracellular matrix
organization through its modulation of integrin-linked kinase
activity. J Biol Chem 280:36483–36493
Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M (1994)
PDGF-BB modulates endothelial proliferation and angiogenesis
in vitro via PDGF beta-receptors. J Cell Biol 125:917–928
Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur
T,SteinGS,LianJB,KommBS(2004)TheWntantagonistsecreted
frizzled-related protein-1 is a negative regulator of trabecular bone
formation in adult mice. Mol Endocrinol 18:1222–1237
Bornstein P, Sage EH (2002) Matricellular proteins: extracellular
modulators of cell function. Curr Opin Cell Biol 14:608–616
Bradshaw AD, Reed MJ, Carbon JG, Pinney E, Brekken RA, Sage
EH (2001) Increased fibrovascular invasion of subcutaneous
polyvinyl alcohol sponges in SPARC-null mice. Wound Repair
Regen 9:522–530
Bradshaw AD, Reed MJ, Sage EH (2002) SPARC-null mice exhibit
accelerated cutaneous wound closure. J Histochem Cytochem 50:1–10
Bradshaw AD, Graves DC, Motamed K, Sage EH (2003a) SPARC-null
mice exhibit increased adiposity without significant differences in
overall body weight. Proc Natl Acad Sci U S A 100:6045–6050
Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, Wight TN,
Helene Sage E (2003b) SPARC-null mice display abnormalities
in the dermis characterized by decreased collagen fibril diameter
and reduced tensile strength. J Invest Dermatol 120:949–955
Cao Y (2007) Angiogenesis modulates adipogenesis and obesity. J
Clin Invest 117:2362–2368
Chavey C, Boucher J, Monthouel-Kartmann MN, Sage EH, Castan-
Laurell I, Valet P, Tartare-Deckert S, Van Obberghen E (2006)
Regulation of secreted protein acidic and rich in cysteine during
adipose conversion and adipose tissue hyperplasia. Obesity
(Silver Spring) 14:1890–1897
Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A (2009) Adipo-
genesis and WNT signalling. Trends Endocrinol Metab 20:16–24
Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED, Weiss SJ
(2006) A pericellular collagenase directs the 3-dimensional
development of white adipose tissue. Cell 125:577–591
Colognato H, Winkelmann DA, Yurchenco PD (1999) Laminin
polymerization induces a receptor-cytoskeleton network. J Cell
Biol 145:619–631
252 J. Nie, E.H. SageDedhar S, Williams B, Hannigan G (1999) Integrin-linked kinase
(ILK): a regulator of integrin and growth-factor signalling.
Trends Cell Biol 9:319–323
Delany AM, Amling M, Priemel M, Howe C, Baron R, Canalis E
(2000) Osteopenia and decreased bone formation in osteonectin-
deficient mice. J Clin Invest 105:915–923
Delany AM, Kalajzic I, Bradshaw AD, Sage EH, Canalis E (2003)
Osteonectin-null mutation compromises osteoblast formation,
maturation, and survival. Endocrinology 144:2588–2596
Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S (1998)
Phosphoinositide-3-OH kinase-dependent regulation of glycogen
synthase kinase 3 and protein kinase B/AKT bythe integrin-linked
kinase. Proc Natl Acad Sci U S A 95:11211–11216
Dong YF, Soung do Y, Schwarz EM, O’Keefe RJ, Drissi H (2006)
Wnt induction of chondrocyte hypertrophy through the Runx2
transcription factor. J Cell Physiol 208:77–86
Farmer SR (2005) Regulation of PPARgamma activity during adipo-
genesis. Int J Obes (Lond) 29(Suppl 1):S13–16
Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V,
Chatterjee K, Garkavtsev I, Jain RK (2003) Paracrine regulation
of angiogenesis and adipocyte differentiation during in vivo
adipogenesis. Circ Res 93:e88–97
Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, Nambiar
P, Rosenberg DW, Bronson RT, Edelmann W, Kucherlapati R,
Gonzalez FJ, Spiegelman BM (2002) APC-dependent suppres-
sion of colon carcinogenesis by PPARgamma. Proc Natl Acad
Sci U S A 99:13771–13776
Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H,
Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G
(2005) Canonical Wnt signaling in differentiated osteoblasts
controls osteoclast differentiation. Dev Cell 8:751–764
Glass DA 2nd, Karsenty G (2006) Canonical Wnt signaling in
osteoblasts is required for osteoclast differentiation. Ann N Y
Acad Sci 1068:117–130
Gregoire FM, Smas CM, Sul HS (1998) Understanding adipocyte
differentiation. Physiol Rev 78:783–809
Hartmann C (2006) A Wnt canon orchestrating osteoblastogenesis.
Trends Cell Biol 16:151–158
Hausman GJ, Richardson RL (2004) Adipose tissue angiogenesis. J
Anim Sci 82:925–934
Hohenester E, Sasaki T, Giudici C, Farndale RW, Bachinger HP
(2008) Structural basis of sequence-specific collagen recognition
by SPARC. Proc Natl Acad Sci U S A 105:18273–18277
Jendraschak E, Sage EH (1996) Regulation of angiogenesis by
SPARC and angiostatin: implications for tumor cell biology.
Semin Cancer Biol 7:139–146
Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald
OA (2007) Wnt signaling stimulates osteoblastogenesis of
mesenchymal precursors by suppressing CCAAT/enhancer-bind-
ing protein alpha and peroxisome proliferator-activated receptor
gamma. J Biol Chem 282:14515–14524
Kawaguchi N, Toriyama K, Nicodemou-Lena E, Inou K, Torii S,
Kitagawa Y (1998) De novo adipogenesis in mice at the site of
injection of basement membrane and basic fibroblast growth
factor. Proc Natl Acad Sci U S A 95:1062–1066
Kennell JA, MacDougald OA (2005) Wnt signaling inhibits adipo-
genesis through beta-catenin-dependent and -independent mech-
anisms. J Biol Chem 280:24004–24010
Keophiphath M, Achard V, Henegar C, Rouault C, Clement K,
Lacasa D (2009) Macrophage-secreted factors promote a
profibrotic phenotype in human preadipocytes. Mol Endocrinol
23:11–24
Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N,
Zhang BB, Bonaldo P, Chua S, Scherer PE (2009) Metabolic
dysregulation and adipose tissue fibrosis: role of collagen VI.
Mol Cell Biol 29:1575–1591
KoloninMG,SahaPK,ChanL,PasqualiniR,ArapW(2004)Reversalof
obesity by targeted ablation of adipose tissue. Nat Med 10:625–632
Kuo HJ, Maslen CL, Keene DR, Glanville RW (1997) Type VI
collagen anchors endothelial basement membranes by interacting
with type IV collagen. J Biol Chem 272:26522–26529
Kupprion C, Motamed K, Sage EH (1998) SPARC (BM-40,
osteonectin) inhibits the mitogenic effect of vascular endothelial
growth factor on microvascular endothelial cells. J Biol Chem
273:29635–29640
Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH (1994) SPARC is a
source of copper-binding peptides that stimulate angiogenesis. J
Cell Biol 125:929–943
Liu J, DeYoung SM, Zhang M, Cheng A, Saltiel AR (2005) Changes
in integrin expression during adipocyte differentiation. Cell
Metab 2:165–177
Liu J, Wang H, Zuo Y, Farmer SR (2006) Functional interaction
between peroxisome proliferator-activated receptor gamma and
beta-catenin. Mol Cell Biol 26:5827–5837
Longo KA, Wright WS, Kang S, Gerin I, Chiang SH, Lucas PC, Opp
MR, MacDougald OA (2004) Wnt10b inhibits development of
white and brown adipose tissues. J Biol Chem 279:35503–35509
Martinek N, Shahab J, Saathoff M, Ringuette M (2008) Haemocyte-
derived SPARC is required for collagen-IV-dependent stability of
basal laminae in Drosophila embryos. J Cell Sci 121:1671–1680
Maurer P, Hohenadl C, Hohenester E, Gohring W, Timpl R, Engel J
(1995) The C-terminal portion of BM-40 (SPARC/osteonectin) is
an autonomously folding and crystallisable domain that binds
calcium and collagen IV. J Mol Biol 253:347–357
Minamitani T, Ikuta T, Saito Y, Takebe G, Sato M, Sawa H, Nishimura
T, Nakamura F, Takahashi K, Ariga H, Matsumoto K (2004)
Modulation of collagen fibrillogenesis by tenascin-X and type VI
collagen. Exp Cell Res 298:305–315
Moldes M, Zuo Y, Morrison RF, Silva D, Park BH, Liu J, Farmer SR
(2003) Peroxisome-proliferator-activated receptor gamma sup-
presses Wnt/beta-catenin signalling during adipogenesis. Bio-
chem J 376:607–613
Nie J, Chang B, Traktuev DO, Sun J, March K, Chan L, Sage EH,
Pasqualini R, Arap W, Kolonin MG (2008) IFATS collection:
Combinatorial peptides identify alpha5beta1 integrin as a
receptor for the matricellular protein SPARC on adipose stromal
cells. Stem Cells 26:2735–2745
Nie J, Sage EH (2009) SPARC inhibits adipogenesis by its enhancement
of beta-catenin signaling. J Biol Chem 284:1279–1290
Nozaki M, Sakurai E, Raisler BJ, Baffi JZ, Witta J, Ogura Y, Brekken
RA, Sage EH, Ambati BK, Ambati J (2006) Loss of SPARC-
mediated VEGFR-1 suppression after injury reveals a novel
antiangiogenic activity of VEGF-A. J Clin Invest 116:422–429
O’Connor KC, Song H, Rosenzweig N, Jansen DA (2003) Extracel-
lular matrix substrata alter adipocyte yield and lipogenesis in
primary cultures of stromal-vascular cells from human adipose.
Biotechnol Lett 25:1967–1972
Oloumi A, McPhee T, Dedhar S (2004) Regulation of E-cadherin
expression and beta-catenin/Tcf transcriptional activity by the
integrin-linked kinase. Biochim Biophys Acta 1691:1–15
Pendas AM, Folgueras AR, Llano E, Caterina J, Frerard F, Rodriguez
F, Astudillo A, Noel A, Birkedal-Hansen H, Lopez-Otin C (2004)
Diet-induced obesity and reduced skin cancer susceptibility in
matrix metalloproteinase 19-deficient mice. Mol Cell Biol
24:5304–5313
Planat-Benard V, Silvestre JS, Cousin B, Andre M, Nibbelink M,
Tamarat R, Clergue M, Manneville C, Saillan-Barreau C, Duriez
M, Tedgui A, Levy B, Penicaud L, Casteilla L (2004) Plasticity of
human adipose lineage cells toward endothelial cells: physiological
and therapeutic perspectives. Circulation 109:656–663
Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH (1992) The
extracellular glycoprotein SPARC interacts with platelet-derived
SPARC functions as an inhibitor of adipogenesis 253growth factor (PDGF)-AB and -BB and inhibits the binding of
PDGF to its receptors. Proc Natl Acad Sci U S A 89:1281–1285
Rempel SA, Golembieski WA, Fisher JL, Maile M, Nakeff A (2001)
SPARC modulates cell growth, attachment and migration of U87
glioma cells on brain extracellular matrix proteins. J Neurooncol
53:149–160
Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E,
Sabatie E, Cano A, Garcia de Herreros A, Ballotti R, Tartare-
Deckert S (2006) SPARC represses E-cadherin and induces
mesenchymal transition during melanoma development. Cancer
Res 66:7516–7523
Rodriguez Fernandez JL, Ben-Ze'ev A (1989) Regulation of fibro-
nectin, integrin and cytoskeleton expression in differentiating
adipocytes: inhibition by extracellular matrix and polylysine.
Differentiation 42:65–74
Rosen ED, Spiegelman BM (2000) Molecular regulation of adipo-
genesis. Annu Rev Cell Dev Biol 16:145–171
Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL,
MacDougald OA (2000) Inhibition of adipogenesis by Wnt
signaling. Science 289:950–953
Sabatelli P, Bonaldo P, Lattanzi G, Braghetta P, Bergamin N,
Capanni C, Mattioli E, Columbaro M, Ognibene A, Pepe G,
Bertini E, Merlini L, Maraldi NM, Squarzoni S (2001)
Collagen VI deficiency affects the organization of fibronectin
in the extracellular matrix of cultured fibroblasts. Matrix Biol
20:475–486
Sage H, Vernon RB, Funk SE, Everitt EA, Angello J (1989) SPARC, a
secreted protein associated with cellular proliferation, inhibits
cell spreading in vitro and exhibits Ca+2-dependent binding to
the extracellular matrix. J Cell Biol 109:341–356
Selvarajan S, Lund LR, Takeuchi T, Craik CS, Werb Z (2001) A
plasma kallikrein-dependent plasminogen cascade required for
adipocyte differentiation. Nat Cell Biol 3:267–275
Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich JN
(2007) Targeting SPARC expression decreases glioma cellular
survival and invasion associated with reduced activities of FAK
and ILK kinases. Oncogene 26:4084–4094
Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG (2006)
Wnt signalling in osteoblasts regulates expression of the receptor
activator of NFkappaB ligand and inhibits osteoclastogenesis in
vitro. J Cell Sci 119:1283–1296
Spiegelman BM, Ginty CA (1983) Fibronectin modulation of cell shape
and lipogenic gene expression in 3T3-adipocytes. Cell 35:657–666
TakahashiM,NagaretaniH,FunahashiT,NishizawaH,MaedaN,Kishida
K, Kuriyama H, Shimomura I, Maeda K, Hotta K, Ouchi N, Kihara
S,NakamuraT,YamashitaS,MatsuzawaY(2001)Theexpressionof
SPARC in adipose tissue and its increased plasma concentration in
patients with coronary artery disease. Obes Res 9:388–393
Tang W, Zeve D, Suh JM, Bosnakovski D, Kyba M, Hammer RE,
Tallquist MD, Graff JM (2008) White fat progenitor cells reside
in the adipose vasculature. Science 322:583–586
Tartare-Deckert S, Chavey C, Monthouel MN, Gautier N, Van
Obberghen E (2001) The matricellular protein SPARC/osteonec-
tin as a newly identified factor up-regulated in obesity. J Biol
Chem 276:22231–22237
Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini
R, Johnstone BH, March KL (2008) A population of multipotent
CD34-positive adipose stromal cells share pericyte and mesen-
chymal surface markers, reside in a periendothelial location, and
stabilize endothelial networks. Circ Res 102:77–85
Weaver MS, Sage EH, Yan Q (2006) Absence of SPARC in lens
epithelial cells results in altered adhesion and extracellular matrix
production in vitro. J Cell Biochem 97:423–432
Weaver MS, Workman G, Sage EH (2008) The copper binding
domain of SPARC mediates cell survival in vitro via interaction
with integrin beta1 and activation of integrin-linked kinase. J
Biol Chem 283:22826–22837
Wilsie LC, Chanchani S, Navaratna D, Orlando RA (2005) Cell
surface heparan sulfate proteoglycans contribute to intracellular
lipid accumulation in adipocytes. Lipids Health Dis 4:2
254 J. Nie, E.H. Sage